JPM Still Cheap, Still Stuck, as UBS Pushes to $400

JPMorgan Chase is heading into the final stretch of Q4 at $337.98, up just 0.65% on the week, with a valuation that continues to look disconnected from the quality of the underlying business.

The analyst community is not hiding its view. UBS's Erika Najarian lifted her target to $400 this week, the most recent in a string of post-earnings upward revisions from Barclays ($425), Morgan Stanley ($377), and Truist Securities ($361). The mean Street target is $373.48, implying roughly 10.5% upside from where the stock closed Tuesday. Citigroup was the exception, trimming to $350 and keeping a Neutral, but the direction of travel across the group is clearly constructive. The PE has nudged down to 13.3 and price-to-book is 2.28, multiples that fit a regional lender better than a franchise generating $15.3 billion in quarterly net income on 20% ROTCE. The analyst_rec_diff factor ranks in the 96th percentile of its universe, meaning consensus relative to the stock's current price is unusually bullish by any historical measure.

The bull case is straightforward. 3Q26 managed revenue of $50.9 billion, a 13.9% CET1 ratio, nearly $7.9 trillion in client assets, and a loan book that FDIC call reports show has grown for nine consecutive quarters to $1.54 trillion. Total deposits, also from FDIC data, have risen for three consecutive quarters to $2.82 trillion. Bears counter that the Q3 print leaned on a $4.6 billion Visa gain and $763 million of equity investment gains; strip those out and core profitability is harder to defend at current multiples. Macro risks compound the scepticism: persistent inflation, potential credit deterioration ahead of a 2027 recession, and regulatory headwinds across its consumer franchise.

Short interest is real but not alarming. Estimated shares short have climbed through 26.7 million, putting SI at just over 1% of free float, the highest level since mid-September and up 14% over the past month. That is a creep worth monitoring rather than a crowd betting against the name. The borrow market confirms the same read: cost to borrow is 0.29%, down 15% on the week and down 30% over the month, and availability is essentially unlimited, with 1.95 billion shares available against a short position of 26.7 million. There is no squeeze mechanics here, no elevated borrow costs, no tightening of supply. Options positioning carries a mild defensive tilt. The put/call ratio is 1.13, about one standard deviation above its 20-day average of 1.08. That is higher than it was in early October, when PCR readings were closer to par, but nowhere near the year-high of 1.47. The setup looks cautious rather than fearful.

One signal genuinely worth flagging is retail attention. The ORTEX alt data mover shows Wikipedia page views running at a z-score of 2.75 against the company's own trailing 90 days, a multi-month high as of October 31. The ORTEX short score is 32, stable and unremarkable. Peers have been mixed on the week: Wells Fargo gained 3.5%, a clear outperformer, while Bank of America fell 2% and Citizens Financial dropped 1.4%. JPM's 0.65% weekly gain sits in the middle of that range, consistent with its recent pattern of holding ground without leading.

The next scheduled earnings event is January 14, 2027, 71 days away. Between now and then, the stock needs either the multiple to expand toward what the Street thinks it's worth, or fresh evidence on net interest income trajectory as rates settle, to give the bulls a catalyst beyond a valuation argument that has been open for two months without closing.